Showing results (341-350 of 471) with videos related to

Sort By:
Pageof 48
Blood Reviews|June 1, 1991
Management of pediatric non-Hodgkin's lymphomaJ Y Blay, D Louis, E Bouffet, et al.
Medicine|November 27, 2025
Heartfulness meditation alters neuroendocrine profiles: A randomized controlled trial on hormones of stress and well-beingSanjana T Philip, Jayaram Thimmapuram, Kapil Thakur, et al.
Bulletin Du Cancer|October 20, 2000
[Huriet law: application in a regional cancer centre (Centre Léon-Bérard, Lyon)]G Chvetzoff, I Ray-Coquard, A Dumortier, et al.
International Journal of Cancer|April 10, 1995
Sensitive detection of numerical and structural aberrations of chromosome 1 in neuroblastoma by interphase fluorescence in situ hybridization. Comparison with restriction fragment length polymorphism and conventional cytogenetic analysesV Combaret, C Turc-Carel, P Thiesse, et al.
Molecular Biotherapy|March 1, 1990
Lymphokine-activated killer cell expansion for clinical trials of adoptive immunotherapy with interleukin-2: optimization of the culture techniqueM C Favrot, C Coze, V Combaret, et al.
Pediatrie|January 1, 1988
[Metastatic neuroblastoma with secondary hypersecretion of vasoactive intestinal peptide]J Brunet, F Saudin, P Cochat, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|December 25, 2025
Inhalable perfluorocarbon RNA nanocapsules overcome biological barriers to treat lung metastasesKasturi Siddhanta, Neha Kumari, Aditya Sundar, et al.
Biorxiv : the Preprint Server for Biology|June 12, 2025
Inhalable Perfluorocarbon Nanocapsules for RNA-based Immunotherapeutic Treatment of Lung MetastasesKasturi Siddhanta, Atefehsadat Monirvaghefi, Aditya Sundar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 1996
Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropeniaJ Y Blay, F Chauvin, A Le Cesne, et al.
Blood|November 10, 1998
The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma GroupJ Blay, F Gomez, C Sebban, et al.
Pageof 48